InvestorsHub Logo
Followers 41
Posts 4235
Boards Moderated 0
Alias Born 08/01/2007

Re: HawkerLaker post# 117503

Tuesday, 08/11/2015 12:21:50 PM

Tuesday, August 11, 2015 12:21:50 PM

Post# of 403017
You are very wrong about the news items that could be released in the very near future.

List compliments of daydreaming2

Catalyst!
Re-Posting:

Q3 Milestones / Upcoming Catalysts

- Start of B-ABSSSI (Phase 3)
- Start of K + cytarabine (Phase 2)
- Completion of K (Phase 1)
- 10-K (mid-September)
- NASDAQ uplisting

Past Milestones

- QIDP designation for B-ABSSSI
- K orphan drug designation for ovarian cancer
- Start of B-OM (Phase 2)
- Start of P (Phase 2)
- B-ABSSSI positive Phase 2b top-line & bottom line data
- Completion of cohort 10 (450 mg/m2)
- P (Phase 1) primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)

Clinical Trials

1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1
1. P (Phase 1, completed): https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=2
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT02324335?term=cellceutix&rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT02052388?term=cellceutix&rank=5

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News